A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Tipus: ASSAIG CLÍNIC Autor: joaquim bosch barrera Centre: Institut Català d'Oncologia (ICO)CARACTERÍSTICAS DE LOS PACIENTES, PATRONES DE TRATAMIENTO Y RESULTADOS DE LOS PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO AVANZADO CON MUTACIONES DE INSERCIÓN EN EL EXÓN 20 DEL EGFR: REVISIÓN ETROSPECTIVA OBSERVACIONAL NO INTERVENCIONISTA DE HISTORIAS CLÍNICAS EN ESPAÑA. ESTUDIO ERMEX-20.
Tipus: ESTUDI OBSERVACIONAL Autor: joaquim bosch barrera Centre: Institut Català d'Oncologia (ICO)ENHANCE: A RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING MAGROLIMAB IN COMBINATION WITH AZACITIDINE VERSUS AZACITIDINE PLUS PLACEBO IN TREATMENT-NAÏVE PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME.
Tipus: ASSAIG CLÍNIC Autor: jordi vila bou Centre: Institut Català d'Oncologia (ICO)ESTUDIO FASE II, ALEATORIZADO, PARA EVALUAR LA INCIDENCIA DE DISCONTINUACIÓN DEBIDA A DIARREA EN LOS 3 PRIMEROS CICLOS DE TRATAMIENTO EN PACIENTES CON CÁNCER DE MAMA PRECOZ HER2 POSITIVO (HER2+), RECEPTOR HORMONAL POSITIVO (RH+), TRATADOS CON NERATINIB MÁS LOPERAMIDA VERSUS NERATINIB CON ESCALADA INICIAL DE DOSIS MÁS LOPERAMIDA (SEGÚN NECESIDAD) VERSUS NERATINIB MÁS LOPERAMIDA MÁS COLESEVELAM
Tipus: ASSAIG CLÍNIC Autor: nÚria sala gonzÁlez Centre: Institut Català d'Oncologia (ICO)A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis IPF
Tipus: ASSAIG CLÍNIC Autor: saioa eizaguirre anton Centre: Hospital Universitari Dr.Josep TruetaA Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib as First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (HCC)
Tipus: ASSAIG CLÍNIC Autor: raquel guardeÑo sÁnchez Centre: Institut Català d'Oncologia (ICO)A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)
Tipus: ASSAIG CLÍNIC Autor: raquel guardeÑo sÁnchez Centre: Institut Català d'Oncologia (ICO)A multicenter, open label, randomized, Phase II trial to investigate soluble LAG-3 fusion protein, eftilagimod alpha (efti; IMP321) in combination with pembrolizumab (PD-1 antagonist) for first line treatment of subjects with unresectable recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC)
Tipus: ASSAIG CLÍNIC Autor: jordi rubiÓ casadevall Centre: Institut Català d'Oncologia (ICO)A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer
Tipus: ASSAIG CLÍNIC Autor: nÚria sala gonzÁlez Centre: Institut Català d'Oncologia (ICO)A multicenter, single-arm, open-label, extension, rollover study to evaluate. The long-term safety and efficacy of Ocrelizumab in patients with multiple Sclerosis
Tipus: ASSAIG CLÍNIC Autor: lluÍs ramiÓ torrentÀ Centre: ICS-IAS UNIEM Unitat de Neuroimmunologia i Esclerosi Múltiple Territorial de Girona (UNIEMTG)A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Tipus: ASSAIG CLÍNIC Autor: pilar barretina ginesta Centre: Institut Català d'Oncologia (ICO)A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer
Tipus: ASSAIG CLÍNIC Autor: pilar barretina ginesta Centre: Institut Català d'Oncologia (ICO)A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Tipus: ASSAIG CLÍNIC Autor: nÚria sala gonzÁlez Centre: Institut Català d'Oncologia (ICO)A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced Non–Small Cell Lung Cancer With an FGFR Alteration Who Progressed on Previous Therapy (FIGHT-210)
Tipus: ASSAIG CLÍNIC Autor: joaquim bosch barrera Centre: Institut Català d'Oncologia (ICO)A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)
Tipus: ASSAIG CLÍNIC Autor: sonia del barco berron Centre: Institut Català d'Oncologia (ICO)A Phase 2b,Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of PRV-015 in Adult Patients with Non-Responsive Celiac Disease as an Adjunct to a Gluten-free Diet
Tipus: ASSAIG CLÍNIC Autor: david busquets casals Centre: Hospital Universitari Dr.Josep TruetaA Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
Tipus: ASSAIG CLÍNIC Autor: josep maria roncero vidal Centre: Institut Català d'Oncologia (ICO)A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF NIVOLUMAB OR PLACEBO IN COMBINATION WITH DOCETAXEL, IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CHECKMATE 7DX:CHECKPOINT PATHWAY AND NIVOLUMAB CLINICAL TRIAL EVALUATION 7DX)
Tipus: ASSAIG CLÍNIC Autor: clÀudia fina planas Centre: Institut Català d'Oncologia (ICO)A Phase 3 Randomized, Open-Label, Multicenter Study comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma who are ineligible for Stem Cell Transplantation
Tipus: ASSAIG CLÍNIC Autor: nichollas john kelleher Centre: Institut Català d'Oncologia (ICO)A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Tipus: ASSAIG CLÍNIC Autor: clÀudia fina planas Centre: Institut Català d'Oncologia (ICO)